Ceribell, Inc. Reports Strong Q2 2025 Revenue Growth

Ceribell, Inc. ( (CBLL) ) has released its Q2 earnings. Here is a breakdown of the information Ceribell, Inc. presented to its investors.

Ceribell, Inc. is a medical technology company specializing in innovative solutions for diagnosing and managing serious neurological conditions, with its flagship product being the Ceribell System, a point-of-care EEG platform. In its second quarter of 2025, Ceribell reported a significant revenue increase of 38% compared to the previous year, reaching $21.2 million. The company also achieved a gross margin of 88% and expanded its active accounts to 584, reflecting strong commercial performance and adoption of its technology. Key financial metrics reveal a rise in product and subscription revenues, with product revenue at $15.9 million and subscription revenue at $5.3 million, both showing substantial year-over-year growth. However, operating expenses increased by 56% due to investments in commercial expansion and public company operations, resulting in a net loss of $13.6 million. Looking ahead, Ceribell has raised its full-year revenue guidance, anticipating growth between 30% and 34%, as it continues to focus on expanding its market presence and advancing its product pipeline.